ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Bausch + Lomb To Acquire ISTA In Cash Deal

DOW JONES NEWSWIRES Bausch + Lomb Monday agreed to acquire ISTA Pharmaceuticals Inc. (ISTA), swooping in with a higher offer for the eye-care company deal less than two months after a rival suitor withdrew its bid. ISTA shares jumped 7.8% to $9.03 after hours, slightly below Bausch + Lomb's $9.10 per-share offer price, which offers more than $380 million for Ista's outstanding shares. That values the company at a roughly 134% premium over its close Dec. 15, the day before ISTA confirmed its was weighing its strategic options. The latest offer comes after Valeant Pharmaceuticals International Inc. (VRX, VRX.T) withdrew a sweetened bid for the eye-care company. Valeant in January raised its offer for ISTA to $7.50 a share, with a target of $8.50 subject to due diligence. ISTA at the time said it would continue to review Valeant's offer, valued at up to $353 million, but said it would remain in talks with a number of parties that expressed interest in a strategic transaction. Basch + Lomb's deal, expected to close in the second quarter, won unanimous approval from both companies' boards. Basch + Lomb said the deal benefits from the two companies' complementary development pipelines. The companies plan to continue operating independently until the deal closes. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; Andrew.FitzGerald@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
04/24/201509:14:00RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment...
04/24/201509:14:00RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment...
04/23/201509:22:05Valeant Pharmaceuticals Intl Given Buy Rating at Cantor Fitzgerald...
04/22/201521:17:45Meet Pharma's Newest Movers and Shakers, Driving M&A
04/22/201520:12:06Meet Pharma's Newest Movers and Shakers, Driving M&A
04/21/201521:46:22Teva Offers to Buy Mylan for $40 Billion -- 5th Update
04/21/201517:47:56Statement of Changes in Beneficial Ownership (4)
04/17/201517:29:38Statement of Changes in Beneficial Ownership (4)
04/14/201508:44:32The Growing Business Of Animal Healthcare
04/13/201517:22:11Amended Statement of Ownership (sc 13g/a)
04/13/201510:36:35Earnings And GDP Temporarily Take Investor Spotlight Off The...
04/09/201512:47:41Proxy Statement (definitive) (def 14a)
04/09/201511:34:49Value Stocks For DIY Investors
04/09/201508:00:00Valeant Pharmaceuticals To Announce 2015 First Quarter Results...
04/09/201508:00:00Valeant Pharmaceuticals To Announce 2015 First Quarter Results...
04/08/201513:36:22Horizon Pharma And Hyperion Therapeutics: Still Upside Or Not?
04/07/201516:55:39Current Report Filing (8-k)
04/05/201509:52:02Can This Pharma Go From Good to Great?
04/03/201516:00:00Seeking Alpha's Biotech Weekly: Billion Dollar Deals, Gilead...
04/02/201515:48:04Statement of Changes in Beneficial Ownership (4)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad